Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of BI 3776528 in Healthy Male Participants
NCT06745297Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2025
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 3776528 (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Treatment-Emergent Adverse Events up to 62 days, Area under the concentration-time curve from zero to the last quantifiable data point up to 27 days and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
BI 3776528
Beyond the preview
Go deeper on NCT06745297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745297.